---
title: "Organon sets 2025 revenue guidance range below consensus"
date: "2025-02-13 17:04:43"
summary: "Organon (NYSE:OGN) revenue guidance range for this year has come in below the consensus estimate. The company sees 2025 revenues of $6.125B-$6.325B. Consensus is $6.43B. In Q4, Organon beat on the bottom line, while the topline was inline. Organon was hurt in the quarter by flat year-over-year sales. The company..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1129585563/image_1129585563.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Organon (NYSE:[OGN](https://seekingalpha.com/symbol/OGN "Organon & Co.")) revenue guidance range for this year has come in below the consensus estimate.
* The company sees 2025 revenues of $6.125B-$6.325B. Consensus is $6.43B.
* In Q4, Organon [beat on the bottom line](https://seekingalpha.com/news/4407604-organon-non-gaap-eps-of-0_90-beats-by-0_03-revenue-of-1_59b-in-line "beat on the bottom line"), while the topline was inline.
* Organon was hurt in the quarter by flat year-over-year sales. The company saw a 37% decline (excluding foreign exchange) in NuvaRing (etonogestrel / ethinyl estradiol vaginal ring) sales due to ongoing generic competition. Biosimilars revenue also fell 18%.
* Organon ended 2024 with cash and cash equivalents of $675M and debt of $8.9B.

[seekalpha](https://seekingalpha.com/news/4407687-organon-sets-2025-revenue-guidance-range-below-consensus)
